Risk of progression differs in high risk and low risk cases when surgery is omitted Ductal carcinoma in situ (DCIS) is a non-obligate precursor lesion of invasive breast cancer. Since the ...

Overview:Ductal carcinoma in situ (DCIS) is a heterogeneous group of diseases that differ in biology and clinical behavior. Until 1980, DCIS represented less than 1% of all breast cancer cases. With ...

Researchers are hoping to find new ways to predict when an early form of breast cancer is likely to progress and develop new treatments for those at risk, thanks to new funding from Breast Cancer Now.

Have you ever heard about a cancer that is "in situ"? There's a reason why it's called that -- and why it's the kind of ...

As a teen, 'Inside Edition' correspondent Alison Hall hated her small breasts. Cancer took them from her at age 32, and she ...

Langley Perer, a beloved Hollywood manager and producer, died June 25, 2025 following a four-year battle with cancer. She was ...

Singer Jessie J. recently shared her breast cancer journey, highlighting the importance of early detection. Breast cancer, a disease where breast cell ...

HER2 tumor marker tests are used to determine whether breast cancer is HER2 positive or negative. A person is a candidate for ...

A West Lothian woman who received a breast cancer diagnosis out of the blue is taking on a marathon-length moonlit challenge.

Aiforia Technologies Plc launches a new CE-IVD marked clinical AI solution for breast cancer grading. Aiforia® Breast Cancer Grading AI solution is a part of the Aiforia® Breast Cancer Suite, which ...

Nick Stone discusses some of the many ways in which light can be used for diagnostic and therapeutic applications ...

The Helsinki-based firm's test is used to automate breast cancer grading using AI-developed models, and it is integrated into the firm's breast cancer suite.